30 closest matches · ranked by relevance
Familial Cold Autoinflammatory Syndrome (FCAS) · Familial Cold Urticaria · Muckle-Wells Syndrome (MWS)
Primary: Change From Baseline to Week-6 (Part A) Endpoint in Mean Key Symptom Score (KSS) — 2.4; 3.1; 2.1; 0.5 Units of a Scale — p=<.0001
Cryopyrin-associated Periodic Syndromes · Familial Cold Autoinflammatory Syndrome · Muckle-Wells Syndrome
Primary: Percentage of Participants Aged 4 Years or Younger With at Least One Complete Response at Week 56 — 94.1 Percentage of participants
Cryopyrin-Associated Periodic Syndromes · Familial Cold Autoinflammatory Syndrome · Muckle Wells Syndrome
Primary: The Number of Participants With Adverse Events (AEs), Death, Serious Adverse Events (SAEs), Discontinuation of Study Drug Due to an AE, Infections and Infestations and…
Cryopyrin-associated Periodic Syndromes · Familial Cold Autoinflammatory Syndrome · Muckle-Wells Syndrome
Primary: The Percentage of Participants Without Disease Relapse as Determined by the Physician's Global Assessment of Autoinflammatory Disease Activity, Assessment of Skin…
Inflammation · Familial Mediterranean Fever · Still's Disease, Adult-Onset
Primary: Mean Change in Daily Scores — -3.09 units on a scale
TNF-receptor Associated Periodic Syndromes (TRAPS)
Primary: Percentage of Participants With Complete or Almost Complete Response at Day 15 — 95 Percentage of participants
Periodic Fevers Syndrome
Primary: Number of Participants With Non-serious Adverse Events, Serious Adverse Events and Deaths — 1; 1; 0; 0 Participants
Hereditary Periodic Fevers
Primary: Percentage of Participants With Resolution of Initial Flare and Absence of New Flares up to the End of the Randomized Treatment Epoch (16 Weeks) — 61.29; 6.25; 35.14…
Mevalonate Kinase Deficiency
Primary: Number of Flares Per Participant During Historical Period and Treatment Period — 5; 0 Number of flares
NLRC4-MAS · XIAP Deficiency
Primary: Prevention of Flares — 2.71; NA Weeks
Familial Mediterranean Fever
Primary: To Assess the Efficacy of Rilonacept in Decreasing the Number of Acute FMF Attacks. — 0.77; 2.00 number of attacks per month — p=0.027
Muckle Wells Syndrome
Primary: Percent of Participants With Disease Flare in Part II (After 24 Weeks of the Double-blind Part) — 0; 81.3 percent of participants
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Measurement of Serum Lactate Dehydrogenase (LDH) — 2913; 3056; 1453; 564 U/L
Systemic Juvenile Idiopathic Arthritis · Hereditary Periodic Fevers
Primary: Number of Participants With Adverse Events — 7; 29 Participants
Paroxysmal Nocturnal Haemoglobinuria (PNH)
Primary: Measurement of Ratio of LDH to the Upper Limit of Normal (ULN) — 5.6; 1.9 Ratio of LDH:ULN (250 U/L)
DIRA
Primary: Number of Subjects Who Maintained Inflammatory Remission With Rilonacept — 6 Participants
Familial Cold Autoinflammatory Syndrome
Primary: Ratio of Fold Change From Pre-challenge to the Highest Post-challenge Value of White Cell Count (WCC) Between Treatment and Screening Period — 0.82 ratio of fold change
Acute Gout
Primary: Time to First New Flare — NA; NA Days
Acute Gout
Primary: Time to First New Flare: Survival Analysis During the 12 Weeks of Study — NA; NA Days
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Primary: Intraepidermal Nerve Fiber Density (IENFD) — -0.6064; -0.396 fibers/mm/year (52 weeks)
Acute Gouty Arthritis
Primary: Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups — 17.1; 32 Millimeters
Scleroderma · Systemic Sclerosis · Diffuse Scleroderma
Primary: Change in 2- Gene Biomarker — -2.67; 0.42 2- gene biomarkers score
Acute Gouty Arthritis
Primary: Number of Participants Who Reported Adverse Events — 78; 65; 64 Participants
Systemic Juvenile Idiopathic Arthritis With Active Flare
Primary: Part I: Percentage of Patients Who Were on Steroids at Entry Into Part I and Who Were Able to Taper Steroid as Per Protocol in at Least 25% of the Patients Who Entered…
Common Variable Immunodeficiency (CVID), APDS / PASLI
Primary: Part I: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 0; 2; 0 Participants
Systemic Juvenile Idiopathic Arthritis
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs by Severity, AEs Leading to Discontinuation, SAEs Leading to Discontinuation…
RheumatoId Arthritis
Primary: DAS28-ESR — 3.75; 3.72; 3.59; 3.69 units on a scale — p=0.82
Antiphospholipid Antibody Syndrome · End Stage Renal Disease
Primary: Number of Patients With Prevention of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) After Kidney Transplant — 1 Participants
Relapsing Polychondritis
Primary: Physician Global Assessment of Disease Activity — 21; 14; 12; 43 mm
Familial Chylomicronemia Syndrome
Primary: Percent Change From Baseline in Fasting Serum Triglyceride (TG) at Month 10 — -85.7; -89.5; 38.8 Percent change — p=0.0022